The tumor suppressor miR-204 inhibits VM in TNBC by targeting HIF-1α and downstream signaling components, including PI3K/AKT, RAF1/MAPK, VEGF-A, and FAK/SRC pathways [35]. Here, VEGFA is linked to neoplasm.